Read more
Informationen zum Autor Gordon Binder is the managing director of Coastview Capital LLC, a venture-capital firm he founded in 2001. From 1982 through 2000, he served as Chief Financial Officer, then Chief Executive Officer, and finally Chairman of Amgen. Forbes magazine counted him among "biotech's most respected business minds." Philip Bashe has authored or co-authored books on a wide variety of genres, including health, sports, biography, and popular culture. Klappentext Widely regarded as the most innovative, successful biotech firm ever, Amgen led its industry in revenue and sales growth in 2007. Top magazines including Fortune and Industry Week have repeatedly named it one of America's best companies to work for.In Science Lessons, Gordon Binder-CEO and chairman during 1988-2000-describes Amgen's climb to success. Revealing the highs and lows it experienced in the race to develop blockbuster drugs, he takes readers from the time Amgen had just three months of capital in the bank and no viable products in the pipeline to its spectacular success. The turning point? The 1989 launch of Epogen, which dramatically helped kidney dialysis patients suffering from debilitating anemia. Other landmark drugs, including Neupogen, would follow. Through engaging anecdotes and cogent insights, Binder weaves a fascinating tale while offering his unique brand of practical management advice. Using the principals of the scientific method, he shares his recommendations for tackling pressing business challenges-such as managing creative employees, navigating the IPO process, and protecting intellectual property.This colorful first-person account showcases the visionary science and daring business strategy that made Amgen great-offering valuable lessons for all companies. Zusammenfassung Widely regarded as an innovative, successful biotech firm, Amgen led its industry in revenue and sales growth in 2007. This book reveals the highs and lows it experienced in the race to develop drugs. It takes readers from the time Amgen had just three months of capital in the bank and no viable products in the pipeline to its success. Inhaltsverzeichnis Introduction Chapter 1: The Start of a Start-up Chapter 2: Amgen Goes Public Chapter 3: The Business of Science/The Science of Business Chapter 4: From IPO to EPO in Four Months Chapter 5: EPO on Trial Chapter 6: Partnerships Made in Heaven - and That Other Place Chapter 7: Red Hot Summer Chapter 8: Nuclear Winter Chapter 9: How to Build a Winning Team (And Keep Them Winning) Chapter 10: How Amgen Kept Employees Committed Chapter 11: The Value of Ethics in Business Chapter 12: My Failed Retirement...
